Literature DB >> 8371519

Marked species-difference in the vascular angiotensin II-forming pathways: humans versus rodents.

H Okunishi1, Y Oka, N Shiota, T Kawamoto, K Song, M Miyazaki.   

Abstract

Using isolated arteries, we demonstrated a marked difference in the angiotensin II-forming systems between human and rodent vessels. In human arteries, only 30-40% of the conversion of angiotensin I to angiotensin II depended on the angiotensin-converting enzyme (ACE), and the rest of the angiotensin II formation was ascribed to chymostatin-sensitive angiotensin II-generating enzyme (CAGE). On the contrary, angiotensin II formation in rodent arteries totally depended upon ACE, without any sign of CAGE involvement. Such a marked species-difference can be relevant to the reported difference between humans and rodents in the ACE inhibitor effects on the myointimal hyperplasia after intimal balloon injury.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8371519     DOI: 10.1254/jjp.62.207

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  12 in total

Review 1.  Optimal strategies for preventing progression of renal disease: should angiotensin converting enzyme inhibitors and angiotensin receptor blockers be used together?

Authors:  R Komers; S Anderson
Journal:  Curr Hypertens Rep       Date:  2000-10       Impact factor: 5.369

2.  Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet.

Authors:  M Lassila; P Finckenberg; A K Pere; L Krogerus; J Ahonen; H Vapaatalo; M L Nurminen
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

3.  A novel vascular smooth muscle chymase is upregulated in hypertensive rats.

Authors:  C Guo; H Ju; D Leung; H Massaeli; M Shi; M Rabinovitch
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

4.  Chymase increases glomerular albumin permeability via protease-activated receptor-2.

Authors:  Ram Sharma; Vidudala Prasad; Ellen T McCarthy; Virginia J Savin; Kottarappat N Dileepan; Daniel J Stechschulte; Elias Lianos; Thomas Wiegmann; Mukut Sharma
Journal:  Mol Cell Biochem       Date:  2006-11-11       Impact factor: 3.396

Review 5.  Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischaemic therapy?

Authors:  W J Remme
Journal:  Drugs       Date:  1997       Impact factor: 9.546

6.  Inhibition of angiotensin converting enzyme cannot prevent increases in angiotensin II production in coronary circulation.

Authors:  Y Hojo; U Ikeda; T Katsuki; O Mizuno; H Fujikawa; K Shimada
Journal:  Heart       Date:  2000-05       Impact factor: 5.994

Review 7.  Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial.

Authors:  B Pitt; P Chang; P B Timmermans
Journal:  Cardiovasc Drugs Ther       Date:  1995-10       Impact factor: 3.727

8.  Suppression of basic fibroblast growth factor-induced angiogenesis by a specific chymase inhibitor, BCEAB, through the chymase-angiotensin-dependent pathway in hamster sponge granulomas.

Authors:  Michiko Muramatsu; Mayumi Yamada; Shinji Takai; Mizuo Miyazaki
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

9.  Cloning of the gene and cDNA for hamster chymase 2, and expression of chymase 1, chymase 2 and angiotensin-converting enzyme in the terminal stage of cardiomyopathic hearts.

Authors:  N Shiota; A Fukamizu; H Okunishi; S Takai; K Murakami; M Miyazaki
Journal:  Biochem J       Date:  1998-07-15       Impact factor: 3.857

10.  Role of chymase in the local renin-angiotensin system in keloids: inhibition of chymase may be an effective therapeutic approach to treat keloids.

Authors:  Ru Wang; Junjie Chen; Zhenyu Zhang; Ying Cen
Journal:  Drug Des Devel Ther       Date:  2015-08-28       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.